Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis, D&A Pharma Prepare For High-Stake EMA Meetings

Executive Summary

Oral explanation meetings are due to take place this week for drug sponsors who have a final chance to address questions and concerns the European Medicines Agency has about their marketing applications.

You may also be interested in...



EMA Crunch Time For Shionogi’s Novel Antibiotic Cefiderocol

The EU marketing application for cefiderocol that lost fast track status last July is now up for an opinion by the European Medicines Agency.

EMA Crunch Time For Shionogi’s Novel Antibiotic Cefiderocol

The EU marketing application for cefiderocol that lost fast track status last July is now up for an opinion by the European Medicines Agency.

Zolgensma Stands Out In Strong Q4 For Novartis

CEO Vas Narasimhan is confident the Swiss major's gene therapy for spinal muscular atrophy will outperform present and future rivals – Biogen's Spinraza and Roche's risdiplam, respectively – as "we have a better profile simply because we are a one-time therapy."

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS141741

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel